Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31134196 | 0.84 | CYP3A4 (0.42) | CYP3A4GSK3BKMT2AMEN1ATR | |
| SCHEMBL31134164 | 0.84 | LMNA (0.55) | CYP3A4GSK3BKMT2AMEN1ATR | |
| SCHEMBL5534604 | 0.78 | PDE4A (0.52) | CYP3A4 | |
| SCHEMBL2743785 | 0.74 | PDE5A (0.49) | — | |
| SCHEMBL28312125 | 0.70 | PDE4A (0.52) | CYP3A4 | |
| SCHEMBL7437553 | 0.70 | GSK3B (0.54) | GSK3BKMT2AMEN1ATRPOLB | |
| SCHEMBL2743668 | 0.70 | GSK3B (0.51) | GSK3BKMT2AMEN1ATRPOLB | |
| SCHEMBL11928777 | 0.70 | PDE4A (0.44) | CYP3A4 | |
| SCHEMBL2743661 | 0.69 | LMNA (0.60) | GSK3BKMT2AMEN1ATRPOLB | |
| SCHEMBL25371015 | 0.69 | CYP3A4 (0.67) | CYP3A4POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178578-B2 | Chemical compounds | THE UNIVERSITY OF MANCHESTER (GB) | 2012-05-15 | — | — | US | disclosed |
| US-20100016261-A1 | CHEMICAL COMPOUNDS | THE UNIVERSITY OF MANCHESTER (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2101755-A2 | POLYALKYLOXYDIBENZ (C,E) OXEPINE DERIVATIVES AS MEDICAMENTS | The University of Manchester (GB) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008075048-A2 | POLYALKYLOXYDIBENZ ( C, E) OXEPINE DERIVATIVES AS MEDICAMENTS | THE UNIVERSITY OF MANCHESTER (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016261-A1 | CHEMICAL COMPOUNDS | CYP11B2, MPO, PIGO | CYP3A4 138/4885GSK3B 2541/4885KMT2A 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.